CVE:DMA DiaMedica Therapeutics (DMA) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free DMA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume27,250 shsAverage Volume6,619 shsMarket CapitalizationC$36.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get DiaMedica Therapeutics alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About DiaMedica TherapeuticsDiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… DMA Stock News HeadlinesFebruary 16, 2024 | morningstar.comDiaMedica Therapeutics Inc DMACMarch 31, 2023 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call TranscriptApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.February 24, 2023 | nasdaq.comCerevel Therapeutics Holdings (CERE) Shares Cross Below 200 DMAOctober 26, 2022 | seekingalpha.comDiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trialAugust 12, 2022 | finance.yahoo.comMEXC Activated the "Investor Protection Fund" in Response to the Dragoma (DMA) Incident, and Launched the "Potion" Airdrop Compensation BenefitsJuly 8, 2022 | marketwatch.comDiaMedica Therapeutics Announces Clinical Hold of DM199 Trial, Shares Fall 31%May 7, 2022 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call TranscriptSee More Headlines Receive DMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:DMA CUSIPN/A CIKN/A Webwww.diamedica.com Phone+1-763-4965454FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.48 Quick Ratio3.37 Sales & Book Value Annual SalesC$503,657.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.33 Book ValueC$0.17 per share Price / BookN/AMiscellaneous Outstanding Shares7,856,880Free FloatN/AMarket CapC$36.38 million OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Rick Pauls M.B.A. (Age 48)MBA, Pres, CEO & Director Dr. Todd A. Verdoorn (Age 58)Chief Scientific Officer Mr. Scott B. Kellen C.A. (Age 54)CFO & Company Sec. Mr. Edward B. Rady (Age 70)Chief Commercial Advisor Dr. Dennis D. Kim M.D. (Age 49)MBA, Consulting Chief Medical Officer Key CompetitorsIBEX TechnologiesCVE:IBTDevonian Health GroupCVE:GSDHelix BioPharmaTSE:HBPMicrobix BiosystemsTSE:MBXAptose BiosciencesTSE:APSView All Competitors This page (CVE:DMA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
